GlycoMimetics Inc (GLYC)
0.3989
0.00 (0.00%)
USD |
NASDAQ |
Nov 13, 16:00
0.405
+0.01
(+1.53%)
After-Hours: 20:00
GlycoMimetics Revenue (TTM)
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2021 | 1.160M |
| September 30, 2021 | 1.305M |
| June 30, 2021 | 2.218M |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 |
| Date | Value |
|---|---|
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | 3.993M |
| September 30, 2013 | 7.804M |
| June 30, 2013 | 11.58M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
1.160M
Minimum
Dec 2021
2.218M
Maximum
Jun 2021
1.561M
Average
1.305M
Median
Sep 2021
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Arbutus Biopharma Corp | 6.742M |
| Revance Therapeutics Inc | 256.94M |
| FibroGen Inc | 173.82M |
| Cidara Therapeutics Inc | 39.07M |